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Abstract 
 
 The Hsp70 family of molecular chaperones is essential for 
protein folding, re-folding misfolded client proteins, clearance of 
aberrant client proteins, and can also inhibit programmed cell death. 
There are two major cytosolic members of this family: the constitutive 
Hsc70, and the inducible Hsp72.  Under stress conditions the Hsp70 
family protects the cell from protein related damage by the induction 
of Hsp72. Hsc70 and Hsp72 are highly homologous with minor 
differences in substrate binding. In cancers, Hsp72 is commonly 
induced and this induction is thought to aid in cancer cell survival. In 
these studies we demonstrate the differential regulation of the pro-
survival kinase Akt by Hsc70 and Hsp72. We demonstrate that of the 
two cytosolic forms, Hsp72 is the primary Akt regulator. Using a 
phenothiazine class inhibitor of Hsp70-family activity, methylene blue, 
we demonstrate dose dependent decreases in the levels of Akt; 
produced breast cancer specific cell death. This cell death could be 
rescued by the use of an Hsp70 family ATPase stimulating compound, 
SW02. We also demonstrate a similar phenotype with a rhodacyanine 
 vii 
class Hsp70 family inhibitor, YM-1, also capable of reducing Akt and 
causing cancer specific cytotoxicity. The resulting Akt decreases were 
sufficient to block a tamoxifen-resistance pathway, allowing previously 
resistant cells to regain sensitivity to tamoxifen. These results 
demonstrate the capabilities of Hsp70 family inhibitors as potent 
compounds for the treatment of breast cancer. 
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Chapter 1: 
 
Introduction 
 
Breast Cancer 
 Breast cancers are among the most diagnosed cancers in women 
(DeSantis et al., 2011). As with most cancers, there is no one cause 
for tumorigenesis across all patients. Though little is known about the 
initiating factors of breast cancer, these cancers often share similar 
aberrant growth and survival pathways. However, there are numerous 
pathways involved in the growth and survival of cancers. Some of 
these pathways have already been targeted by therapeutics. However, 
there are few therapies that can effectively target all varieties and 
variations of breast cancer as there are few targets or pathway 
elements that are common across multiple survival systems. 
 One of these commonalities is the expression of estrogen 
receptor (ER) α, or lack-there-of. Approximately 75% of breast 
cancers express estrogen receptor (Miller et al., 2011). Estrogen 
dependent growth can be targeted with therapeutics. Antagonizing 
ligand binding to ER (tamoxifen), downregulating ER (fulvestrant), or 
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preventing the synthesis of estradiol (aromatase inhibitors) are all 
strategies used to treat ER+ tumors (Miller et al., 2011). However, 
these strategies are not perfect as more than 30% of patients with 
ER+ breast cancers relapse within 15 years of tamoxifen therapy, and 
17% of patients treated with aromatase inhibitors relapse within 9 
years (EBCTCG, 2005; Forbes et al., 2008). While the exact nature of 
these resistance mechanisms is still unknown, with some hypotheses 
described later, one pathway is often implicated as a factor in these 
resistances (along with general tumor cell survival), the 
phosphatidylinositol 3-kinase (PI3K) pathway. 
 
Survival and Growth Factors 
 The PI3K pathway is activated by various growth factor receptor 
tyrosine kinases and G-protein coupled receptors. This activation 
prompts PI3K to phosphorylate phosphatidylinositol 4,5-bisphosphate 
(PIP2) to yield phosphatidylinositol 3,4,5-triphosphate (PIP3) (Whitman 
et al., 1988). The formation of PIP3 recruits proteins containing a 
unique domain known as the pleckstrin-homology (PH) domain to the 
cell membrane where PIP3 is located. Binding of PH domain-containing 
proteins to PIP3 cue the activation mechanisms for some PH proteins 
(Marte and Downward, 1997). 
 3 
 One of these proteins, Akt (protein kinase B/Akt), is a major 
cytosolic kinase capable of regulating numerous pathways. These Akt-
regulated pathways can control cell metabolism, growth, death, and 
mobility (Yoeli-Lerner and Toker, 2006). Akt performs these abilities in 
both normal and cancer cell alike. However, the aforementioned 
aberrant pathways involved in breast cancer, along with the underlying 
tumorigenic factor itself, often can lead to Akt dysfunction (She et al., 
2008). This dysfunction leads to enhanced cellular growth, metabolism 
and mobility; all while preventing cell death. This is the phenotype of 
most cancer cells. In these cases, a cell cannot undergo the pre-
programmed cell death pathways that should have been triggered to 
prevent the cancer cell formation. Akt is at the center of this death 
prevention while simultaneously causing the cells to grow out of 
control. 
 Targeting Akt as with therapeutics appears to be promising, from 
a distance. The Akt family of kinses is comprised of three members: 
Akt1 (PKBα), Akt2 (PKBß), and Akt3 (PKBγ) (reviewed in Dillon et al., 
2007). Of these members, Akt1 and Akt2 are highly involved in the 
growth and death pathways of tumor cells (Heron-Milhavet et al., 
2011). Akt1 and Akt2 exhibit a high degree of homology with some 
redundancy; though recent work has identified complementary 
opposing functions between these two members (Heron-Milhavet et 
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al., 2011; Maroulakou et al., 2008; Maroulakou et al., 2007). This 
redundancy is one of the two main reasons targeting Akt has proved 
difficult in that removal of one variant does not block the systems 
regulated by Akt. The other main hurdle is the inhibitory abilities 
balanced between Akt1 and Akt2. Akt1 has been shown to play an 
important role in breast cancer induction, whereas Akt2 promotes 
migration of cancer cells. (Hutchinson et al., 2001; Hutchinson et al., 
2004). However, Akt1 has been shown to inhibit the migratory 
regulation of Akt2, such that when Akt1 is silenced or specifically 
inhibited tumor cells are more migratory (Dillon et al., 2009). A similar 
phenomena occurs when targeting or silencing Akt2. Akt2 slows the 
ability of Akt1 to regulate tumor growth; thus silencing or inhibiting 
Akt2 leads to enhanced tumor growth, due to Akt1 (Dillon and Muller, 
2010). For these reasons, individual inhibitors to specific Akt 
members, again, fail to offer relief to multiple pathogenic factors. 
Targeting total Akt might be a plausible strategy. 
 Again, Akt is activated through the PH domain interaction with 
PIP3. Mutations found in this domain, in PI3K, or deletion of  the 
phosphatase and tensin homologue (PTEN - the phosphatase 
responsible for the reversion of PIP3 to PIP2) can cause all Akt 
members to become constitutively active (Carnero, 2010). As the PI3K 
pathway is the most frequently altered pathway in breast cancer 
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(Miller et al., 2011), inhibitors to PI3K have been identified. While 
these compounds have demonstrated efficacy both in the lab and in 
clinical trials (Liu et al., 2009) they only alter one specific pathway 
which promotes aberrant Akt activity. To identify new therapeutics 
that can regulate all Akt members, we would have to look beyond 
targets that regulate Akt activity. We would need to alter the stability 
of Akt to then prevent the genesis of aberrant Akt. 
 
Molecular Chaperones 
 Molecular chaperones serve as the protein quality control 
system. These chaperones identify improperly folded or denatured 
proteins. These “misfolded” proteins are refolded or degraded to 
prevent damage to the cellular environment (Kampinga and Craig, 
2010). Chaperones are also responsible for the initial folding of some 
proteins. These newly transcribed genes require chaperone 
interactions immediately during translation. Other proteins often 
interact with chaperones spanning the entire term of existence. All of 
these proteins, commonly termed ‘clients’, are often sensitive to 
changes in the chaperone network as their stability is dependent on 
the activity of these chaperones.  
 Akt is a well documented client of the chaperone system. Work 
conducted by our lab elucidated the mechanisms for Akt degraded by 
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chaperone manipulation (Dickey et al., 2008). However, the 
mechanisms used to facilitate this degradation, though used as a 
cancer therapy, are not an ideal strategy for treating cancers; as will 
be discussed. 
 The molecular chaperone system is comprised of several large 
families of chaperones. Work from our lab detailed the role of the 90-
kDa heat shock proteins (Hsp90) in regulating Akt. Hsp90 is a known 
regulator of multiple client proteins and is often implicated as having a 
role in the pathogenesis of a number of maladies. Our work detailed 
the use of Hsp90 inhibitors; compounds which inhibit the hydrolysis of 
adenosine tri-phosphate (ATP) by Hsp90, a process necessary for 
Hsp90 activity. This inhibition promotes Akt degradation via a ubiquitin 
ligase known as CHIP (carboxy-terminus of Hsc70 interacting protein). 
CHIP ligates ubiquitin to client proteins which are to be degraded by 
the proteasome. This is a common degradation mechanism for 
misfolded or aberrant proteins. 
 Similar to Hsp90, the 70-kDa heat shock protein (Hsp70) family 
is involved in Akt stability. Hsp70 family members are ubiquitously 
expressed through out all tissues with specific varieties targeted to 
select organelles (Daugaard et al., 2007; Kampinga and Craig, 2010). 
Hsp70 has two major members in the cytosol, Hsc70 (Hsp73) and 
Hsp70 (Hsp72). Hsc70 is expressed across all tissues and is known as 
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the constitutive member of the cytosolic Hsp70 members. Hsp70 is the 
stress inducible form of the cytosolic Hsp70 members. Under stress, 
originally heat as the moniker indicates, a stress factor, HSF (heat 
shock factor) is released from the constitutive chaperones. HSF 
translocates to the nucleus where it binds the heat-shock-element 
promoting the transcription of the inducible heat shock proteins, 
namely Hsp70. This induction is how cells prevent total loss of function 
under high heat conditions. Heat will denature tertiary protein 
structure. Chaperones refold the denatured proteins, stabilizing the 
once lost tertiary structure. 
 
Stress and the Cancer Cell 
 A cancer cell is a stressed cell. Often, this stress causes cancer 
cells to have elevated levels of Hsp70. In cancer, Hsp70 has been 
shown to act in an anti-apoptotic capacity; this along side the cancer 
cells need for protein homeostasis under stress (Sherman and 
Multhoff, 2007). This anti-apoptotic action is through the interaction of 
Hsp70 with pro-death proteins such as Smac/DIABLO and the 
caspases (Dudeja et al., 2009; Jiang et al., 2009; Rashmi et al., 
2004). Smac/DIABLO and the caspases can be activated to drive 
apoptosis through, among other initiators, mitochondrial damage 
(Chen and Huerta, 2009; Galluzzi et al., 2006). Hsp70, in the instance 
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of Smac/DIABLO activation, was shown to inhibit the activity of 
Smac/DIABLO following mitochondrial damage, thus preventing 
apoptosis (Jiang et al., 2009). 
 There is evidence suggesting Hsp70, and the constitutive Hsc70, 
play a role in regulating Akt (Shiota et al., 2010). Hsc70 has been 
shown to interact with the PH domain; and in a certain instance inhibit 
the activity of that PH protein (Kauppinen et al., 2005). Also, our 
group identified that CHIP is the ubiquitin ligase necessary for Akt 
degradation following Hsp90 inhibition (Dickey et al., 2008). CHIP was 
originally identified as an interacting partner of Hsc70 (Ballinger et al., 
1999). These findings coupled with the induction of Hsp70, a robust 
increase in levels due to HSF release from Hsp90, following inhibition 
of Hsp90 (Zou et al., 1998) suggest that the cytosolic Hsp70 family 
members are highly involved in Akt stability. 
 
Hsp70 Inhibitors 
 As mentioned, Hsp90 inhibitors clear Akt by promoting the 
degradation of Akt by the proteasome. This occurs via ubiquitination 
regulated by the ubiquitin ligase CHIP. While Hsp90 inhibitors are in 
clinical trials for the treatment of numerous cancers (Pacey et al., 
2010; Pacey et al., 2011; Rajan et al., 2011) and can clear total Akt 
(Dickey et al., 2008), the induction of the anti-apoptotic Hsp70 
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consistently observed following Hsp90 inhibition (so consistently, that 
measuring Hsp70 levels is often used as a marker to identify a 
successful Hsp90 inhibitor (Powers and Workman, 2007)) could reduce 
the efficacy of Hsp90 inhibitors as cancer therapeutics since Hsp72 
induction can act to inhibit cell death. This demonstrates the potential 
for why Hsp70 should be the target of inhibitors. Some cancer cells 
have shown sensitivity to silencing of Hsp72 by siRNA (Wei et al., 
1995). It has also been shown that dual silencing of Hsc70 with Hsp72 
yields cell death (Powers et al., 2008). 
 We have conducted work with multiple chemical scaffolds 
designed to inhibit the ATPase activity of the cytosolic Hsp70 family 
members. These inhibitors were able to clear a pathogenic client of 
Hsp70, the microtubule-associated protein τ (MAPT/tau) a 
neurodegenerative factor of Alzheimer’s disease (Jinwal et al., 
2009)(see also Appendices A and B for more information on the 
regulation of tau by the co/chaperone network). Interestingly, Akt and 
tau were found to compete for the same degradation machinery and 
Hsp90 inhibition has the same effect on both clients (Dickey et al., 
2008). Thus, Hsp70 inhibition could reduce the levels of Akt while 
preventing the anti-apoptotic abilities observed with Hsp70. To study 
this mechanism we will also utilize compounds which stimulate the 
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ATPase activity of Hsp70. These compounds should produce an effect 
opposite to the ATPase inhibitors. 
 Inhibiting the ATPase activity of Hsp70 locks Hsp70 into a 
conformation that allows neither the release of a bound client nor can 
Hsp70 interact with a new client. This substrate blockade is regulated 
by the C-terminal “lid” for the substrate binding domain. ATP is 
hydrolyzed to ADP in the N-terminal ATPase domain of Hsp70. This 
hydrolysis drives the closing of the “lid” to the high affinity state. 
Release of substrate, via “lid” opening, is achieved by the replacing of 
ADP with ATP in the nucleotide binding domain (reviewed in Daugaard 
et al., 2007; Kampinga and Craig, 2010). This exchange is facilitated 
by nucleotide exchange factors which can be chaperones or co-
chaperones (Liberek et al., 1991). 
 The interaction of Hsp70 with PH domain containing proteins and 
the observed interactions between Hsp70 and Akt (Gao and Newton, 
2002) suggests that if the ATPase activity of Hsp70 is inhibited the 
interaction between Hsp70 and Akt will be lost. If the interaction 
between Akt and Hsp70 is required for Akt stability, the resulting loss 
of stability could drive Akt degradation. A second possible mechanism 
exists for these Hsp70 inhibitors. If these inhibitors block the exchange 
of ADP for ATP, which could produce similar effects on an ATPase 
assay as an actual ATPase inhibitor, then any substrate bound to 
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Hsp70 at the instance of compound interaction would be locked with 
Hsp70. Losing the ability to release a bound client could also likely 
signal for the degradation of the bound client as well as the 
degradation of the now non-functional Hsp70. While this is entirely 
speculation, the degradation of the tau protein following Hsp70 
inhibition suggests that one of these mechanisms is at work. 
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Chapter 21: 
 
Facilitating Akt clearance via manipulation of Hsp70 activity 
and levels 
 
Abstract 
 Members of the 70-kDa heat shock family can control and 
manipulate a host of oncogenic client proteins.  This role of Hsp70 in 
both the folding and degradation of these client proteins makes it a 
potential drug target for certain forms of cancer.  The phenothiazine 
family of compounds, as well as the flavonoid, myricetin, was recently 
shown to inhibit Hsp70-ATPase activity, while members of the 
dihydropyrimidine family stimulated ATPase function.  Akt, a major 
survival kinase, was found to be under the regulation of Hsp70 and 
when the ATPase activity of Hsp70 was increased or decreased by 
these compounds, Akt levels respectively followed. Also, increasing 
Hsp70 levels concurrent with inhibition of its ATPase function 
                                                             
1Portions of this work were previously published (John Koren III, Umesh K. Jinwal, Ying Jin, John O’Leary, 
Jeff R. Jones, Amelia G. Johnson, Laura J. Blair, Jose F. Abisambra, Lyra Chang, Yoshinari Miyata, Anna M. 
Cheng, Jianping Guo, Jin Q. Cheng, Jason E. Gestwicki, & Chad A. Dickey. Journal of Biological Chemistry 
2010 Jan 22;285(4):2498-505.) and are used with permissioin of the publisher. 
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synergistically reduced Akt levels to a greater extent than either 
manipulation alone, providing new insights about client fate decisions. 
Akt reductions mediated by Hsp70 inhibitors were prevented when 
Hsp70 expression was silenced with siRNA. Inhibiting Hsp70 ATPase 
function produced cytotoxic events only in breast cancer cell lines 
where Akt dysfunction was previously shown, suggesting therapeutic 
specificity depending on the Hsp70 client profile. Thus increasing 
Hsp70 levels combined with inhibiting its ATPase function may serve to 
dramatically reduce Akt levels and facilitate cell death in certain types 
of cancer. 
 
Introduction 
 Heat shock proteins are the primary regulators of protein folding 
and degradation in the cell. The ATPase activity of Hsp70 and Hsp90 
variants serves as the hub whereby all other chaperones and 
cochaperones act upon, either to facilitate recycling or clearance of 
chaperone substrates, or clients. Much of the effort surrounding 
chaperone research has focused on either altering the expression 
levels of these heat shock proteins by activating the heat shock 
transcription factor (HSF1) or by inhibiting the activity of Hsp90 
(Grenert et al.; Zou et al.). Small molecules have been identified that 
can produce either or both of these outcomes (Bagatell et al.; Sittler et 
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al.). However, despite its clear role in a number of diseases of aging, 
very little emphasis has been placed on the enzymatic ATPase activity 
of Hsp70.  To address this deficiency, we recently identified several 
compounds that could either stimulate or inhibit Hsp70 ATPase 
function without affecting its levels (Jinwal et al., 2009). These 
compounds bind to Hsp70 allosterically, affecting the rate of ATP 
consumption, which is tied to opening and closing of the protein lid 
over the substrate binding domain. When ATP is converted to ADP, the 
lid closes, preventing release of the client. When ADP is exchanged for 
ATP, the lid opens and the client is released. We demonstrated that 
Hsp70 inhibitors force this lid to stay open, while activators increase 
the rate of lid opening and closing (Jinwal et al., 2009). With these 
compounds defined, we are now able to compare the effects of 
increasing Hsp70 expression levels with modulating its ATPase function 
for distinct disease-related clients.   
 With this in mind, and based on previous findings that the pro-
survival kinase, Akt, was a well-established substrate of the chaperone 
network (Ballinger et al., 1999; Cyr et al., 2002; Dickey et al., 2006; 
Qian et al., 2006), we contrasted the impact of both Hsp70 expression 
and activity on Akt stability (Dai et al., 2003; Dickey et al., 2008; Min 
et al., 2008).  Because kinases in general have traditionally been 
viewed as Hsp90 clients, most of the existing literature has focused on 
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this relationship; however, more recent work suggests that not only is 
the heat shock-inducible form of Hsp70 (Hsp72) influencing cell 
survival and Akt levels, but the constitutive variant, Hsc70, might also 
be playing a role (Powers et al.). Interestingly, our investigations here 
using a siRNA screening assay initially suggested that these two 
extremely similar Hsp70 variants were having opposing activities on 
Akt protein levels. This unexpected result led us to further explore the 
relationship, and we have found that inducible Hsp70 is a critical 
mediator of Akt proteostasis. Then, using our newly described Hsp70 
inhibitors, we discovered a second mechanistic paradox between 
Hsp70 levels and function. Lastly, we show that inhibiting Hsp70 
ATPase function can rapidly and selectively kill cancer cells that are 
dependent on Akt for survival. Together, these results provide new 
mechanistic and therapeutic insights into the relationship between 
chaperones and Akt.   
 
Materials and Methods 
Cell Lines 
 The Hs578T breast cancer cell line and the syngenic non-cancer 
control Hs578Bst fibroblast line collected from the unaffected breast of 
the same patient (Hackett et al., 1977) were obtained from ATCC.  We 
also utilized MDA-MB-231, MDA-MB-468, MDA-MB-361, MCF7 and 
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MDA-MB-453 cells (Yang et al., 2004). HeLa cells were also obtained 
ATCC. 
 
Antibodies, Plasmids, siRNAs and Chemicals 
 Anti-Hsp70 and anti-Hsc70 antibodies were purchased from 
Steressgen (Ann Arbor, MI) and Anti-Akt (total Akt - #9272) antibody 
was purchased from Cell Signaling Technology and all were used at 
1:1000 dilutions.  Anti-actin antibody was obtained from Sigma Aldrich 
(St. Louis, MO) and used at a 1:1000 dilution.  All antibodies were 
diluted in 7% nonfat dry milk in TBS solution. CA-Akt plasmid is a 
constitutively active, via myristolation, form of mouse Akt-1, was 
provided by Ben Wolozin (Boston University, Boston). All siRNAs were 
acquired from Qiagen and were previously described and characterized 
at a 20nM final concentration (Dickey et al., 2007; Jinwal et al., 2009).  
Methylene Blue was obtained from Fisher Scientific.  Azure C, SW02, 
115-7C and myricetin were previously described (Jinwal et al., 2009). 
KNK-437 was obtained from Sigma Aldrich. 
 
Cell Culture and Transfections 
 Hs578T and MCF-7cells were grown in DMEM containing 10% 
FBS, 1% PenStrep (Gibco), and 0.01mg/mL bovine insulin (Sigma 
Aldrich).  Hs578Bst cells were grown in HybriCare media (ATCC) 
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containing 10% FBS, 1% PenStrep and 30ng/mL epidermal growth 
factor (Sigma Aldrich). MDA-MB-468, MDA-MB-361 and MDA-MB453 
cell were grown in DMEM containing 10% FBS and 1% PenStrep.  HeLa 
cells were grown in Opti-MEM media containing 10% FBS and 1% 
PenStrep.  MDA-MB-231 and T47D cells were grown in RPMI 1640 
media containing 10% FBS and 1% PenStrep.  SiRNA transfections 
were performed using SilentFect (BioRad) and left to incubate for 48 
hours before harvest or treatment; with the exception of the KNK-437 
experiment where 100µM of the reagent was added 24 hours post 
transfection. Plasmid transfections were performed using 
Lipofectamine 2000 (Invitrogen) using 1ug plasmid per reaction; cells 
were left to incubate for 48 hours before harvest or drug treatment. 
 
Protein Collection, Quantitation and Western Blotting 
 Supernatants of selected experiments were harvested using 
MPER (Invitrogen) containing phosphatase inhibitor cocktail 1 and 2 
(Sigma Aldrich) at 1:100, protease inhibitor cocktail set III at 1:100 
(Calbiochem) and PMSF (Fisher BioReagents) at 1:100.  Protein levels 
of the lysates were measured using the Pierce BCA kit.  All proteins 
were standardized following BCA in BupH modified PBS (Thermo). 
Western blotting was performed by running SDS-PAGE, followed by 
transfer, followed by probing with antibodies and visualization by ECL 
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(SignaGen). Western Blot quantitation was performed using Scion 
Image for Windows (Scion Corporation) version Alpha 4.0.3.2. 
 
In-Cell Western (ICW) 
 SiRNA and SilentFect were mixed in serum free media at a ratio 
of 20nM to 1µl and distributed into indicated wells. Suspended HeLa 
cells were added to these mixtures and incubated for 72 hours. Media 
was removed from adherent cells and an In-Cell Western assay was 
performed as previously described (Dickey et al., 2005). Rabbit Anti-
Akt antibody (1:500 as determined from Figure C1) and Mouse 
GAPDH antibody (1:1000) from BioDesign were incubated overnight. 
Secondary antibodies labeled with near-infrared fluorophores were 
applied at 1:500 (Anti-rabbit AlexaFluor 680 from Molecular Probes 
and Anti-mouse IR800CW from Rockland). Plates were imaged using 
the LiCor Odyssey system.      
 
LDH Assay. 
 Breast cancer cell lines were plated in using their designated 
medias, according to ATCC. Once cells reached ~95% confluency, 
methylene blue or vehicle treatments were applied in fresh serum free 
Opti-MEM (Invitrogen) media. 6 hours later, media was collected and 
centrifuged to pellet dead cells.  Supernatant was then added to 96-
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well plate in triplicate along with reagents from Cytotox96 kit 
(Promega) following the supplied protocol. 
 
Results 
Hsp70 and Hsc70 reciprocally affect Akt levels 
 Previous work from our lab and others suggested that Akt was 
critically modulated by the chaperone network (Beliakoff and Whitesell, 
2004; Dickey et al., 2008; Gao and Newton, 2002).  To determine 
which chaperones and chaperone-related proteins were most effective 
at regulating Akt stability we developed an ICW assay to screen 
chaperone siRNAs in a standard HeLa cell line, which was selected for 
its high transfection efficiency, high levels of endogenous Akt and 
robust properties of adhesion and viability to withstand a semi-high 
throughput procedure (i.e. multiple washing steps, shaking, etc.; 
Figure C1). Using this system, we found that siRNAs for Hsp70 or 
Hsc70 respectively increased or decreased endogenous Akt levels by 
~30%. Akt siRNA resulted in ~75% knockdown. Both Hsp90 and CHIP 
siRNA also caused reductions in Akt levels, although to a lesser extent 
than Hsc70. Hsp27 siRNA also increased Akt levels. Neither Bag1 nor 
HSF1 siRNA had any effect on endogenous Akt levels. Akt levels were 
normalized to GAPDH and increases or decreases are shown as a 
percentage of the non-silencing control (Figure 2.1A-D). These 
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findings coupled with our hypothesis that the Hsp70 family of proteins 
may be involved in Akt stability led us to further investigate their 
relationship. 
 
Hsc70 modulates Akt levels indirectly via Hsp70 
 To confirm our ICW results, we analyzed lysates from HeLa cells 
transfected with either Hsc70 siRNA, Hsp70 siRNA or a non-silencing 
control by Western blot. Akt levels confirmed the results from our ICW, 
showing increased levels of Akt in the presence of Hsp70 siRNA and 
decreased Akt levels in the presence of Hsc70 siRNA (Figure 2.2A).  
Specific knockdown was confirmed for both siRNAs using Hsp and 
Hsc70 antibodies. Interestingly, this analysis revealed that Hsp70 
levels were increased when Hsc70 was knocked down, while Hsc70 
levels seemed unaffected by Hsp70 knockdown. To probe this further, 
we over-expressed Hsp or Hsc70 and explored not only the effects on 
Akt, but also their effects on each other. Indeed, Hsp70 over-
expression decreased Akt levels, while Hsc70 increased Akt levels, 
reciprocal to the siRNA results (Figure 2.2B & C). Moreover, 
increasing the level of Hsc70 decreased Hsp70 levels, again opposing 
the results seen with siRNA. This suggested that the effects of Hsc70 
on Akt were actually an indirect consequence of increasing Hsp70 
expression. We considered two possible mechanisms for this; either 
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Hsc70 was contributing to Hsp70 turnover, or it was regulating Hsp70 
transcription. To test the latter, cells transfected with either Hsc70 
siRNA or a non-silencing control were treated with vehicle or KNK-437, 
a compound that inhibits heat shock transcription by blocking the 
binding of HSF1 to heat shock elements (HSE) in Hsp promoters 
(Ohnishi et al., 2004; Voyer and Heikkila, 2008; Yokota et al., 2000). 
Western blot analysis showed that Akt clearance mediated by Hsc70 
siRNA was blocked when Hsp70 transcription was inhibited, indicating 
that Hsp70, not Hsc70, was critically linked to Akt stability (Figure 
2.2D). Therefore we endeavored to further explore how Hsp70 might 
be involved in fate decisions for Akt and what role, if any, this has in 
altering cell viability. 
 
Inhibition of Hsp70ATPase function reduces Akt levels 
 To determine whether Hsp70 levels and ATPase function could 
converge to regulate Akt stability, we analyzed Akt levels in HeLa cells 
following treatment with a group of recently identified Hsp70 ATPase 
chemical modulators (Jinwal et al., 2009). Interestingly, Hsp70 ATPase 
inhibitors (methylene blue (MB) and myricetin (Myr)) caused robust 
decreases in Akt levels in a dose dependent manner (Figure 2.3A). 
These reductions were evident within 1 hour (Figure 2.3B). 
Reductions were more pronounced over a 48 hour time course with 
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MB; however, the flavonoid, Myr, lost activity after 24 hours (Figure 
2.3C & D), likely due to the inherent instability of all flavonoid 
compounds (Boulton et al., 1999). Because of the robust activity 
demonstrated by MB, further studies defining the mechanisms involved 
in Hsp70-mediated Akt clearance focused on this compound and its 
demethylated derivative, Azure C (AC).  
 
Activators of Hsp70 ATPase function facilitate Akt accumulation  
 From our previous chemical screening platform (Chang et al., 
2008; Jinwal et al., 2009), we not only identified inhibitors of Hsp70 
ATPase function, but also activators. Therefore we tested the effects of 
these dihydropyrimidine activators, SW02 and 1157C, on Akt levels in 
HeLa cells. These activators, along with MB and AC, were incubated 
with cells at two doses (10µM and 50µM) for 24hrs. Activation of 
Hsp70 ATPase function with SW02 and 1157c increased Akt levels in a 
dose dependent manner, relative to vehicle, while Hsp70 inhibition 
with MB and AC reduced Akt levels (Figure 2.4A & B). Time course 
analyses for 50µM doses of 1157C and SW02 showed accumulation of 
Akt levels over time (Figure 2.4C & D). These results were somewhat 
unexpected since Hsp70 over-expression caused a similar outcome for 
Akt stability as did Hsp70 enzymatic inhibition, while Hsp70 activation 
preserved Akt levels. One obvious explanation would be that the drugs 
 27 
are simply having off-target effects, which could not be over-looked 
given that MB and Myr can both regulate mitochondrial respiration. To 
address this issue, we investigated whether over-expression of Hsp70 
combined with Hsp70 inhibition synergistically reduced Akt levels. A 
dose response analysis was performed with MB and AC in cells 
transfected with myc-tagged Hsp70 or empty vector. We indeed found 
that while Hsp70 did decrease Akt levels, inhibition of Hsp70 ATPase 
activity coupled with its over-expression was more effective than 
either alone (Figure C2); however, this still did not definitively show 
that MB and AC were working via Hsp70 to reduce Akt levels. There 
was still a possibility that both manipulations were simply facilitating 
Akt clearance through two distinct pathways. 
 
Despite pluripotency, phenothiazines primarily affect Akt via Hsp70 
modulation 
 To definitively address whether MB and AC were regulating Akt 
levels by inhibiting Hsp70 ATPase function, we again turned to siRNA. 
We suppressed Hsp70 expression in HeLa cells with Hsp70 siRNA and 
performed a dose response study with MB. Indeed, Hsp70 siRNA 
almost completely blocked MB-mediated decreases in Akt, relative to 
cells transfected with a non-silencing control (Figure 2.5A & B). 
Subsequent investigation of this phenomenon with both MB and AC 
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showed that Hsp70, not Hsc70, was necessary for Hsp70-inhibitor-
mediated Akt reductions (Figure 2.5C & D). In fact, Hsc70 siRNA 
actually increased Hsp70 inhibitor efficacy, due to the increase in 
Hsp70 levels caused by Hsc70 knockdown. Thus, Hsp70 over-
expression and Hsp70 ATPase inhibition can converge to reduce the 
pro-survival kinase Akt in cells. While paradoxical, these results can 
actually be explained quite elegantly when considering the properties 
of Hsp70 itself and our recent data with these compounds and the 
microtubule associated protein tau ((Jinwal et al., 2009); see Figure 
2.7 and the discussion for more detail regarding the model). One final 
aspect of these studies was to test the potential therapeutic 
application of these inhibitors in cancer cells whose survival is 
dependent on high levels of Akt activity. 
 
Phenothiazines selectively kill breast cancer cells  
 While heat shock proteins have traditionally been deemed 
“protective” for cells, the results from our previous experiments 
indicated that cancer cell lines, in which Akt has been found to be 
critical for cell survival, may be uniquely sensitive to Hsp70 inhibition 
with MB. We analyzed the effects of Hsp70 inhibition on cell survival 
using 7 breast cancer lines. We emphasized the Hs578T cell line 
because it has high levels of active Akt (Zhang et al., 2007), and we 
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previously showed effects with CHIP and Hsp90 inhibitors in this line 
(Dickey et al., 2008). We compared the effects of MB on the Hs578T 
line with the Hs578Bst fibroblast line, which was isolated from the 
opposite breast of the same patient. The effects of MB on the Hs578T 
cells were dramatic; cells appeared morbid and non-adherent after 
only 1hr of a 50µM MB treatment with nearly complete cell death after 
24hrs. The Hs578Bst line on the other hand was completely unaffected 
by treatment. We turned to LDH analysis to quantitatively show the 
cytotoxicity. Cells were again treated with a 50µM concentration of MB 
for 6 hours and LDH analysis showed double the amount of LDH in 
spent media compared to that of the Hs578Bst media (Figure 2.6A). 
We then investigated the effects of Hsp70 inhibition on additional 
breast cancer cell lines with Akt dysfunction; MDA-MB-453, MDA-MB-
361, MCF7, MDA-MB-468, MDA-MB-231, MCF-7, T47D and MDA-MB-
361. Indeed, increased cytotoxicity was observed in each of these cell 
lines to varying degrees, with the three estrogen receptor (+) cell lines 
(MCF-7, T47D and MDA-MB-361) being the most affected (Figure 
2.6B).  Since, we did not observe MB mediated toxicity in other 
standard cell lines, such as HeLa and HEK293 (not shown), we 
speculated that it was indeed Akt that was essential for survival in 
these particular breast cancer cells. To test this, we over-expressed 
constitutively active Akt (CA-Akt) in the Hs578T line, and performed a 
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dose-response analysis with MB, again measuring LDH levels. We 
found that at lower doses, Akt over-expression could abrogate 
cytotoxicity (Figure 2.6C) despite the poor DNA transfection 
efficiency of this cells line (only ~25% increase in expression). In fact, 
the higher 25µM dose was able to override the low levels of CA-Akt. 
We then made a second attempt to rescue the cytotoxic effects of 
Hsp70 inhibition by pre-treating Hs578T cells with the Hsp70 ATPase 
activator, SW02, 24 hours in advance of MB treatment.  We found that 
activating Hsp70 function prior to treating with an inhibitor completely 
blocked the cytotoxicity previously seen at matching doses of MB 
(Figure 2.6D). These data indicated that inhibition of Hsp70 by MB 
could reduce Akt levels and kill specific cancer types that require Akt 
for survival. Moreover, we were able to rescue these effects by over-
expressing Akt or activating Hsp70 ATPase function. 
 
Discussion 
 Here we have demonstrated for the first time that inhibition of 
Hsp70 ATPase activity and Hsp70 over-expression can each facilitate 
reductions in Akt stability. The ability of Hsp70 ATPase inhibitors to 
promote Akt clearance was dependent on the levels of Hsp70 in the 
cell. We also demonstrated that activating Hsp70 ATPase function 
increases Akt levels. Moreover, using a newly developed ICW assay for 
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analysis of siRNAs targeting important chaperones, we found that 
Hsc70 and Hsp70 could differentially regulate Akt levels. Hsp27 siRNA 
also appeared to increase Akt levels. In subsequent analyses, we 
demonstrated that Akt reductions caused by Hsc70 siRNA were a direct 
result of a compensatory increase in Hsp70 levels via heat shock factor 
activation. We also demonstrate that certain breast cancer cell types 
having high levels of active Akt may be susceptible to Hsp70 inhibition. 
Ultimately, these studies suggest that Hsp70 is intimately involved 
with Akt stability and modulating its levels and activity may be a 
relevant therapeutic strategy for the treatment of breast cancer. 
 The most interesting aspect of this study is the initially 
confounding result that Hsp70 over-expression and inhibition of its 
activity could lead to the same outcome for Akt. In fact, based on our 
preliminary data with Hsp70 over-expression, we initially speculated 
that Hsp70 activators would decrease Akt levels, while inhibitors would 
preserve it. However, these results, coupled with our findings with the 
tau protein, suggest a mechanism that may change the way chaperone 
biology is currently viewed. The mechanisms that facilitate the decision 
of the Hsp70 complex to allow degradation or refolding a protein are 
not known. It is only known that the rate of hydrolysis and turnover of 
ATP can push the complex in either direction; more ATP consumption, 
more refolding; less ATP consumption, more degradation. Our data 
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here, when placed in the context of our recent findings with the tau 
protein suggest an intriguing possibility: The nature of a specific client 
along with the state of the cellular environment can be destructive or 
productive. Some clients, like tau, may mostly be targeted for re-
folding. Therefore, tau levels are not dramatically reduced when Hsp70 
levels are increased, because this only produces more pro-folding 
Hsp70/tau complexes that are not degraded; however when we inhibit 
the ATPase activity of Hsp70, this forces the release of tau from 
Hsp70, leading to its degradation (Jinwal et al., 2009). Conversely, 
because Hsp70 over-expression did reduce Akt levels, we would 
speculate that Akt is typically targeted for degradation.  Then, when 
we inhibit Hsp70 ATPase function, the remaining pool of Hsp70/Akt 
complexes that was being targeted for re-folding is forced toward 
degradation, leading to further decreases in Akt levels. This principle is 
depicted graphically in Figure 2.7. Therefore, what initially seemed 
paradoxical could actually shed new light on an area that is essential 
for our complete understanding of the chaperone process; how Hsp70 
and Hsp90 “decide” when to promote degradation or refolding by 
accessory co-chaperones.  
 In addition to this interesting mechanistic insight, there are 
logical comparisons with this work that could be drawn to Hsp90 
inhibitors (Workman, 2004). 17-allyl-amino-17-
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demethoxygelanamycin (17AAG), a specific Hsp90 ATPase inhibitor, 
has shown efficacy for reducing cell survival proteins such as Akt 
(Pelicano et al., 2006), propelling it to clinical trials as a potential 
therapy for various cancers (Modi et al., 2007; Sharp and Workman, 
2006; Yano et al., 1996). However, there seem to be several 
important distinctions between Hsp70 and Hsp90 inhibition. For 
example, since Hsp90 normally functions to bind HSF1 and prevent its 
translocation to the nucleus (Bagatell et al., 2000), Hsp90 inhibition 
induces a stress response while Hsp70 inhibition does not. In fact, 
despite uncertainty about efficacy, this feature alone has prompted the 
use of 17-AAG in breast cancer trials simply as a heat shock inducer 
rather than an Hsp90 inhibitor (Ciocca et al., 1993; Gabai et al., 2009; 
Munster et al., 2001; Vargas-Roig et al., 1997). In addition to this 
major functional difference between Hsp70 and Hsp90, these proteins 
also possess unique structures, binding partners and ATPase turnover 
kinetics. Despite these critical differences, the line separating these 
two proteins is often blurred when discussing the functional differences 
between them. Perhaps now, with these tools at our disposal, we can 
begin to further define the precise differences between Hsp70 and 
Hsp90 function in a way that was not previously possible. 
 This notion of functional redundancy is even more common when 
discussing Hsp70 and Hsc70, which often are used interchangeably in 
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the literature.  These proteins are extremely similar structurally, which 
suggests they also have similar functions.  However, while these 
proteins may function similarly at the biochemical level, as we and 
others have shown, there are interesting differences between these 
two proteins with regard to the role of Hsc70 in regulating Hsp70 
expression.  For example, silencing of Hsp70 increased levels of Her2 
in SKBr3 cells while, Hsc70 silencing decreased these levels in the 
same cell line (Havik and Bramham, 2007).  Moreover, our data here 
shows that Hsc70 is involved in Hsp70 expression, but not vice versa, 
suggesting that Hsc70 is possibly a more dominant form. Perhaps 
Hsp70 levels are partially regulated based on the existing levels of 
Hsc70 (Havik and Bramham, 2007; Powers et al., 2008).  It is Hsp70, 
however, that appears to have the greater impact on Akt as seen by 
the increases in Akt levels when Hsp70 is silenced and the decreases 
in Akt when Hsp70 is induced or over-expressed.  Hsc70’s activity on 
Akt regulation appears to only exist via induction of Hsp70 expression. 
It is important to note as well that the chemicals used in these studies 
are not selective for Hsc70 or Hsp70; they do inhibit both enzymes 
(Chang et al.). Despite this, Hsp70 levels are not affected by these 
inhibitors (Figure 2.5), suggesting that the induction in Hsp70 caused 
by Hsc70 siRNA is due to reduced levels of Hsc70, not activity. Thus, 
Hsc70 and Hsp70 levels may be equally important for regulating Akt 
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stability, but Hsp70 seems more likely to have a direct association with 
this important kinase. 
 Another consideration from these studies is that both Akt and 
Hsp70 have demonstrated pro-survival functions in certain cell types. 
Recent evidence suggests that Hsp70 and Hsc70 play a role in 
preventing apoptosis, a process in which Akt is also intimately 
associated (Powers et al., 2008).  Hsp70 can bind to the apoptosis 
precursor DIABLO (Smac) and the presence of a functional Hsp70 
ATPase domain can prevent cell death (Jiang et al., 2009).  This 
suggests that an induction of Hsp70, by any means, would potentially 
be working against apoptosis. Therefore, at first glance, it is somewhat 
counter-intuitive that Hsp70 over-expression and inhibition would both 
lead to reductions in Akt levels, since Akt is known to promote cell 
survival; this function would likely antagonize any anti-apoptotic 
function of Hsp70. However, our results seem to point to a mechanism 
whereby the oncogenic client repertoire involved in specific types of 
cancer may be predictive of Hsp70 inhibitor efficacy: In other words, in 
tumor cells that are dependent on Akt activation for transformation 
and survival (similar to that found in the Hs578T line and the MDA-MB 
lines), Hsp70 over-expression combined with Hsp70 inhibition may be 
a very effective therapeutic strategy, simply because this would 
eliminate more Akt; however, either strategy may be entirely 
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ineffective, or even detrimental, in other types of cancer. This aspect 
is an important consideration when attempting to manipulate 
oncogenic client proteins through modifications of the chaperone 
network. Given the low toxicity profile of MB in humans, this strategy 
could quickly move to the clinic for certain cancers based on client 
composition. Knowing whether chaperone clients are contributing to 
the initiation of oncogenic processes could be predictive of clinical 
success with chaperone-based therapies.  
 Finally, it is important to consider that MB and Myr both are 
pluripotent compounds, affecting mitochondrial function, as well as a 
number of other processes in the cell (Kelner et al., 1988; Salaris et 
al., 1991; Visarius et al., 1997). Therefore we cannot rule out that 
these “non-Hsp70” effects are contributing to cell death; however, our 
ability to rescue cell death by activating Hsp70 ATPase function 
suggests that Hsp70 inhibition is a primary activity of MB and related 
phenothiazine scaffolds, which is likely to prime certain cancer types 
for death. While a therapeutic strategy involving Hsp70 for cancer 
requires additional validation, as well as identification of more specific 
compounds, our data support the idea that promoting Hsp70 levels 
combined with inhibiting its activity is potentially an effective strategy 
for reducing aberrant Akt levels in certain cancer types.  
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Figure 2.1. Small scale siRNA screen reveals opposing effects of Hsp70 and 
Hsc70 on Akt levels. HeLa cells were plated in 96-well plates at ~40% confluency 
and transfected with indicated siRNAs for 72 hours. SiRNAs have been previously 
validated by Western blot in this cell line.  In-Cell Western analysis for Akt (A; Red) 
and GAPDH (B; Green) showed ~30% increase in Akt levels when Hsp70 or Hsp27 
was knocked down and as ~30% decrease in Akt levels when Hsc70 was knocked 
down.  Hsc70 siRNA decreased Akt levels most potently.  An overlaid image of Akt 
and GAPDH is presented for contrast (C).  Triplicate wells were quantified and all 
values are shown as a percent of control siRNA (Ctrl) after GAPDH normalization ± 
SD (D). 
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Figure 2.2.  Silencing and overexpression of Hsp70 and Hsc70 inversely 
affect Akt and each other; effect is blocked by heat shock transcription 
inhibition.  HeLa cells, , were transfected with Hsp70 or Hsc70 siRNA or a non-
silencing control siRNA for 48 hours then analyzed by Western blot (20µg 
protein/lane) (A). HeLa cells, at ~90% confluency, were transfected with Hsp70 and 
Hsc70 expression vectors for 48 hours and analyzed by Western Blot (40µg 
protein/lane) (B).  Akt levels resulting from the overexpression of Hsp70 and Hsc70 
data were quantitated ± SD (C). HeLa cells, at ~50% confluency, were transfected 
with siRNA for Hsc70 or a non-silencing control; at the time of transfection, cells 
were treated with either vehicle or 100µM heat shock element (HSE) inhibitor KNK-
437 for 48 hours; results were analyzed by Western Blot (20µg protein/lane) (D). 
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Figure 2.3. Hsp70 ATPase inhibitors show reductions in Akt levels in HeLa 
cells. Structure of methylene blue (MB) and myricetin (Myr) pictured at top. A 6-
hour dose response was performed with MB (A) or Myr (C) at indicated 
concentrations in HeLa cells,. A time course of 50µM MB (B) or Myr (D) was also 
performed at indicated time points in HeLa cells.  6 hour Myr dose response at 
indicated dosages in HeLa cells, treated at ~90% confluency. All blots contained 
20µg protein/lane. 
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Figure 2.4.  Hsp70 ATPase activators display effects opposite those of 
inhibitors.  HeLa cells, at ~90% confluency, were treated for 24 hours with 10 and 
50µM of Hsp70 ATPase inhibitors (MB or AC) or Hsp70 activators (SW02 or 115-7C) 
and lysates were analyzed by Western blot (A). Quantitation was performed using 
pixel density analysis and is shown as a percentage of vehicle treated cells ± SD (  - 
inhibitor,  - activator) (B).  HeLa cells, at ~90% confluency, were treated with 
50µM doses of either SW02 or 115-7C and analyzed by Western blot (C). 
Quantitation was performed using pixel density analysis and is shown as a 
percentage of vehicle treated cells ± SD (  - 1157c,  - SW02) (D). All blots 
contained 20µg protein/lane. 
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Figure 2.5. Efficacy of Hsp70 ATPase inhibitors is dependant on levels of 
Hsp70.  HeLa cells, at ~50% confluency, were transfected with Hsp70 siRNA or a 
non-silencing control (Ctrl) and were then treated with increasing doses of MB as 
indicated. Lysates were analyzed by Western blot (A), and Akt levels as a percent of 
vehicle ± SD following pixel density analysis (  - Hsp70 siRNA,  - Ctrl siRNA) (B).  
HeLa cells, at ~50% confluency, were transfected with non-silencing siRNA (Ctrl), 
Hsp70 siRNA or Hsc70 siRNA for 48 hours, and then were treated with 50µM MB, AC 
or vehicle (C). Results were analyzed by Western blot and quantitation of Akt levels 
by pixel density analysis is shown as a percentage of corresponding vehicle 
treatments (grey bar – MB, black bar – AC) (D). All blots contained 20µg 
protein/lane. 
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Figure 2.6. Hsp70 inhibitors produce Akt-dependent cytotoxicity in breast 
cancer cell lines. LDH assays were performed on media from Hs578Bst and Hs578T 
cell lines, both at ~90% confluency, treated with 50µM MB or vehicle for 6 hours and 
levels are shown as a percent of vehicle treated cells ± SD (A). LDH assays were 
performed on media from MDA-MB-468, MDA-MB-231, MDA-MB-453, MCF-7, T47D, 
and MDA-MB-361 cell lines, all at ~90% confluency, treated with 50µM MB or vehicle 
for 6 hours. LDH levels are shown as a percent of vehicle treated cells ± SD and ER 
expression (B). LDH assays were performed on media collected from Hs578T cells 
transiently transfected at ~90% confluency with either a 6TR non-coding vector or a 
myristolated Akt vector (CA-Akt) and treated with increasing dosages of MB or a 
vehicle control for 6 hours. LDH levels are shown as a percent of cells overexpressing 
CA-Akt relative to treatment matched 6TR control transfected cells ± SD. Inset 
verifies Akt overexpression by pixel density analysis of western blot run on cells 
receiving vehicle treatment (C). LDH assays were performed on Hs578T cells, at 
~90% confluency, receiving a 24 hour 50µM dose of Hsp70 ATPase activator SW02 
(gray bars) or vehicle (black bars) followed by 6 hour dose response treatment of 
Hsp70 ATPase inhibitor MB or vehicle. LDH levels are shown as a percent of vehicle ± 
SD (D). P values were determined by Student t-test. All blots contained 20µg 
protein/lane. 
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Figure 2.7. Model for targeting clients towards destructive or productive 
pathways via Hsp70. As distinct clients (ex: Client 1 and Client 2) are bound by 
Hsp70, there are two distinct fates which can emerge based on the client. These 
fates can be classified as either pro-folding or pro-degradation. The biochemical 
nature of the client bound to Hsp70 along with the state of the cellular environment 
are the key factors which guide the Hsp70/client complex towards a fate: pro-folding 
for those designated to be lead away from potentially non-productive mis-folding 
pathways; or pro-degradation for those requiring turnover as indicated by internal 
mechanisms. However, the exact mechanisms contributing to either of these 
decisions are unknown. Increasing the levels of Hsp70 is more likely to decrease 
certain clients while preserving others. By chemically modulating the ATPase activity 
of Hsp70, we are able to dictate client fate. Hsp70 activators can promote the 
accumulation of clients that would normally be degraded by Hsp70. Hsp70 inhibitors 
can promote the degradation of clients that would normally be preserved. Thus 
Hsp70 over-expression combined with Hsp70 inhibition would synergistically affect 
clients that typically prefer degradation. Conversely, for clients that are more prone 
to re-folding, over-expression of Hsp70 would have minimal impact on the levels of 
these clients, but inhibition of Hsp70 ATPase function would cause reductions. 
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Chapter 32: 
 
Rhodacyanine MKT-077 Derivative, YM-1, Selectively Targets 
Cancer Cells 
 
Abstract 
 MKT-077, a rhodacyanine dye, was shown to produce cancer 
specific cell death. However, complications prevented the use of this 
compound beyond clinical trials. Here we describe YM-1, a derivative 
of MKT-077. We found that YM-1 was more cytotoxic and localized 
differently than both MKT-077 and methylene blue (MB). YM-1 
demonstrated cytotoxicity across multiple cancer cell lines. The 
obserrved toxicity was limited to cancer cell lines; immortalized cell 
models were unaffected. This toxicity was thought to be Akt (Akt/PKB) 
dependent as total Akt levels were reduced. These Akt reductions were 
dependent on Hsp72. YM-1 failed to clear other known breast cancer 
oncogenes as potently as the observed Akt clearance. The Akt 
                                                             
2 Portions of these results were previously published (John Koren III, Yoshinari Miyata, Janine Kiray, John 
C. O’Leary III, Lana Nguyen, Jianping Guo, Laura J. Blair, Xioakai Li, Umesh K. Jinwal, Jin Q. Cheng, Jason 
E. Gestwicki, Chad A. Dickey. PLoS One. 2012;7(4):e35566. Epub 2012) and are used with permission of 
the publisher. 
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clearance combined with the enhanced cytotoxicity demonstrates the 
need to further study the rhodacyanine scaffold. Modifications to the 
rhodacyanines could potentially be made to improve efficacy and 
pharmacokinetic properties. 
 
Introduction 
 MKT-077, a cationic rhodacyanine, has demonstrated cancer 
specific toxicity and growth inhibition in vitro and in vivo across 
multiple cancer varieties (Koya et al., 1996). It was determined that 
MKT-077 localized to the mitochondria (Koya et al., 1996). MKT-077 
entered into clinical trials for the treatment of advanced and refractory 
solid tumors of various cellular origin, including: kidney, lung, 
prostate, colon, adenocarcinomas, and melanomas (Britten et al., 
2000; Propper et al., 1999). The primary negative side effect observed 
in both studies was renal toxicity (Britten et al., 2000; Propper et al., 
1999). The observed toxicity halted recruitment to one trial as similar 
animal studies showed irreversible renal toxicity following 
administration of MKT-077 (Britten et al., 2000; Propper et al., 1999). 
Later it was discovered that MKT-077 interacted with mortalin (mot-2), 
a 70-kda heat shock protein (Hsp70) family member, and that the 
interaction of MKT-077 with mot-2 induced the release of the tumor 
suppressor p53 from a complex with mot-2 (Wadhwa et al., 2000). 
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This mot-2/p53 complex inactivated the tumor suppression abilities of 
p53 by sequestering it in the cytosol in vivo (Wadhwa et al., 1998).  
 Breast cancers are among the most common cancers diagnosed 
in women (DeSantis et al., 2011). Published data states that treating 
MCF7 cells, a breast cancer cell model, with MKT-077 produces 
cytotoxicity and alters growth (Britten et al., 2000; Koya et al., 1996). 
However, in the results of two published Phase I clinical trials, no 
patients with a solid breast tumor or refractory breast tumor were 
included in the study (Britten et al., 2000; Propper et al., 1999).  
 In these data, we identify a functional derivative of MKT-077 
that showed increased cytotoxicity across multiple cancer varieties 
while still retaining the cancer specificity associated with MKT-077. 
This enhanced activity was due to the intracellular localization of the 
compound. One way in which these compounds are working is by 
reducing total Akt levels. The rhodacyanine scaffold holds great 
potential as a cancer therapeutic both as an individual treatment 
strategy but also, potentially, as a combinational or synergistic option 
for use with existing regimens.  
 
Methods 
Cell Lines 
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 The MCF7, HEK-293, M17, H4, MDA-MB-231, Hs578T and NIH-
3T3 cells were purchased from ATCC (Manassas, VA). HeLa cells were 
generously provided by Dr. Kenneth E. Ugen at the University of South 
Florida. He originally obtained them from ATCC (Manassas, VA). 
 
Chemicals, Antibodies and siRNA 
 Methylene blue (MB) was purchased from Sigma Aldrich (St. 
Louis, MO). MKT-077 and YM-1 were synthesized as described 
(Kawakami et al., 1998). Anti-Akt1, Akt2, pAktS473, and RAS were 
purchased from Cell Signaling Technology (Danvers, MA). Anti-ERα 
and p53 were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). Anti-Actin was purchased from Sigma Aldrich. Anti-GAPDH was 
purchased from Meridian Life Science (Memphis, TN). All siRNAs were 
purchased from Qiagen and used as previously described (Koren et al., 
2010). 
 
Cell Culture and Drug Treatments 
 MCF7, MDA-MB-231, Hs578T and HeLa cells were grown as 
previously described (Koren et al., 2010). H4 and HEK-293 cells were 
cultured in OPTI - modified Eagle’s medium (OPTI-MEM) from 
Invitrogen supplemented with 10% fetal bovine serum (FBS) and 1% 
PenStrep (Invitrogen). M17 cells were cultured in OPTI-MEM 
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supplemented with 10% FBS, 1% PenStrep and 100mg/L Sodium 
Pyruvate.  NIH-3T3 cells were cultured in DMEM with low-sodium 
bicarbonate (1.5g/L) from ATCC supplemented with 10% FBS and 1% 
PenStrep. MKT-077, YM-1, and MB were dissolved in DMSO. DMSO 
was used as vehicle for MKT-077 and YM-1 where indicated. Exact 
treatment strategies accompany data in results section. 
 
Mitochondrial Isolation and Spectrophotometry 
 MCF7 cells were treated for 6 hours with vehicle (DMSO), MB, 
YM-1, or MKT-077. Following treatment cells were harvested and 
subcellular fractions collected using Pierce Mitochondrial Isolation Kit 
from Thermo Scientific (Rockford, IL). Analysis of drug localization was 
performed by spectroscopy on Thermo Scientific Nanodrop 
spectrophotometer using the unique absorbance properties of the 
three compounds. Concentrations and subsequent percentages were 
approximated by generated concentration:absorbance curve (not 
shown). 
 
Protein Collection, Quantitation, and Western Blotting 
 Cells were harvested by application of mammalian protein 
extraction reagent (Thermo) as previously described (Koren et al., 
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2010). Protein level measurement, equilibration, western blotting, and 
detection were performed as previously described (Koren et al., 2010). 
 
Lactate Dehydrogenase (LDH) Assay 
 Indicated cell lines were plated in designated medium. Once cells 
reached ~95% confluency, MKT-077 or YM-1 was applied in DMEM 
without phenol red. At times indicated per experiment, medium was 
collected from each treatment and centrifuged to pellet dead cells and 
debris. Protocol was followed as supplied from Cytotox-96 kit 
(Promega). 
 
Results 
Improved Cytotoxicity of YM-1 Over Known Hsp70 Inhibitors 
 The cytotoxicity profiles of a series of derivatives to MKT-077 on 
MCF7 cells were compared in a small-scale screen. The derivative YM-1 
(Figure 3.1A) was found to have dose dependently toxicity levels 
higher than MKT-077 after 24 hours (Figure 3.1B). We then 
compared the toxicity of YM-1 with another Hsp70 inhibitor, methylene 
blue (MB), a compound previously reported for producing cancer 
specific toxicity (Koren et al., 2010). YM-1 demonstrated a higher dose 
dependent toxicity than MB (Figure 3.1C).  
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Altered Location of Action; Cancer Cell Specificity Maintained 
 One possible reason for this improved potency was cellular 
localization. Taking advantage of the unique spectral properties of 
these compounds, MCF7 cells were treated with MKT-077, YM-1 and 
MB then fractionation of mitochondria from cytosol was performed. 
Both MB and MKT-077 are known to localize to the mitochondria; thus 
they can be utilized as controls (Gabrielli et al., 2004; Koya et al., 
1996). The subcellular fractions were analyzed by spectrophotometer 
for the presence of the unique color prorties of each of the 
compounds. These values were compared with a generated standard 
curve of Abs:concentration (data not shown) to give an approximate 
concentration of compound in each fraction and thus a percentage of 
drug per location. Interestingly, YM-1, unlike MKT-077 was more 
prevalent in the cytosolic fractions (Figure 3.2A). 
 Concerned that the lack of mitochondrial interaction would 
reduce the cytotoxic specificity seen with rhodacyanines for cancer 
cells, the selectivity of YM-1 on several cancer and immortalized cells 
lines were tested. These included: Hs578T and MDA-MB-231 (breast 
cancer), M17 (neuroblastoma), H4 (neuroglioma), HeLa (cervical 
cancer), and two immortalized cell lines: HEK 293 (human embryonic 
kidney) and NIH 3T3 (murine fibroblast). The cancer cell lines tested 
all displayed toxicity following YM-1 administration; whereas, the two 
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immortalized cell lines displayed minimal to no toxicity by LDH assay 
(Figure 3.2B). This demonstrated that the cytosolic localization of 
YM-1 did not affect its specificity for cancer cells. 
 
YM-1 Reduces Akt Members; Greater Efficacy than Methylene Blue 
 Based on these results and our previous findings (Koren et al., 
2010), we speculated that the cytotoxicity observed in the breast 
cancer cell lines was Akt-dependent. MCF7 cells were treated with YM-
1 (1, 3 and 10µM) for 6 hours, prior to onset of overt cytotoxicity 
(data not shown). Lysates were analyzed by Western blot. Levels of 
Akt1, Akt2, and Akt phosphorylated at S473, a site necessary for Akt 
activity, were all reduced by YM-1 treatment (Figure 3.3A & B). The 
effective concentrations were lower than those of  MB (Figure 
3.3C)(Koren et al., 2010).  
 
YM-1 Dependent on Hsp72 to Clear Akt; Does Not Clear Other 
Oncogenes 
 We previously demonstrated that the reductions in Akt observed 
following MB treatment were dependent on the levels of Hsp70 (Koren 
et al., 2010). Thus, we conducted an experiment as performed 
previously, silencing Hsp72 and treating with an Hsp70 inhibitor. 
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Interestingly, the Akt reductions observed after YM-1 treatment were 
dependent on Hsp72 levels; similar to MB (Figure 3.4A & B). 
 Given the role of the Hsp70 family in regulating a large number 
of clients within the cell, we speculated that other oncoproteins might 
be contributing to the phenotype produced by YM-1. Levels of p53, 
Ras, and ERα were all assessed by Western blot. All changes in the 
levels of these proteins were negligible compared to Akt (Figure 3.4C 
& D). Thus, a major effect of YM-1 is to potently destabilize Akt, 
suggesting that Akt is an especially sensitive client of the Hsp70 family 
and the effects observed on cell viability are largely dependent on Akt 
clearance. 
 
Discussion 
 Here we describe the therapeutic potential of an MKT-077 
derivative, YM-1. This compound, similar to MKT-077, was specifically 
toxic to cancer cells. YM-1 also had greater efficacy and cytosolic 
localization than MKT-077 and MB. YM-1 was able to reduce the levels 
of Akt but not of other known oncoproteins; this via Hsp70 dependent 
mechanisms. 
 It is possible that the cytosolic presence of YM-1, versus 
mitochondrial of MKT-077, drives the increased toxicity and Akt 
clearance observe with YM-1. Though the mitochondrial aspects of 
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MKT-077 are well characterized (Britten et al., 2000; Koya et al., 
1996; Propper et al., 1999), recent data suggests that MKT-077 can 
also interact with cytosolic Hsp70 family members (Rousaki et al., 
2011). If YM-1 is able to inhibit cytosolic Hsp70 as MKT-077 does 
mortalin (Wadhwa et al., 2000; Wadhwa et al., 1998), the enhanced 
efficacy of YM-1 could be due to this dual interaction. Hsp70 inhibitors 
have demonstrated cancer specificity as well as the ability to reduce 
Hsp70 client proteins (Jinwal et al., 2009; Koren et al., 2010; Leu et 
al., 2009; Leu et al., 2011); thus we assume that the mode of action 
for YM-1 is as a cytosolic Hsp70 inhibitor. 
 These studies demonstrate the need for more mechanistic 
insight into the mode of action of rhodacyanines. Minor changes 
between MKT-077 and YM-1 lead to an increased cytosolic presence 
that was able to maintain similar specificity. This suggests that 
modifications to this scaffold could elicit specific toxicity or reduce 
renal toxicity, as observed in the clinical and laboratory trials (Britten 
et al., 2000; Koya et al., 1996; Propper et al., 1999). In fact, our data 
demonstrating an almost preferential killing of breast cancer cells, 
versus other cancer cell types, suggests that specificity for particular 
tumor varieties could be built into the rhodacyanine scaffold. 
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Figure 3.1. MKT-077 derivative, YM-1, shows enhanced toxicity. Illustrated 
structure of YM-1 (A). MCF7 cells were treated for 24 hours with three concentrations 
of MKT-077 or YM-1. After 24 hours, medium was collected and analyzed by LDH 
assay. Values shown are a % of vehicle treatment ± SD (B). MCF7 cells were treated 
for 24 hours with three concentrations of MB or YM-1. After 24 hours, medium was 
collected and analyzed by LDH assay. Values shown are a % of vehicle treatment ± 
SD (C). 
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Figure 3.2. YM-1 localization doesn’t alter cancer specific toxicity; non-
cancer cells unaffected. MCF7 cells were treated with MKT-077, YM-1 or 
methylene blue (MB). Mitochondrial fractions were collected and compound location 
was measured by spectrophotometer (A). Hs578T and MDA-MB-231 (breast cancer), 
M17 (neuroblastoma), H4 (neuroglioma), and HeLa (cervical cancer) cell treated with 
increasing concentrations of YM-1 and the toxicity was compared to NIH-3T3 (mouse 
embryonic fibroblast) and HEK 293 (human embryonic kidney) cells for cancer 
specific toxicity. All cell lines were treated for 24 hours. After 24 hours, media were 
collected and analyzed by LDH assay. Values shown are a % of vehicle treatment ± 
SD (B).
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Figure 3.3. Akt members are concentration dependently reduced by YM-1; 
dependent on Hsp70. MCF7 cells were treated with noted concentrations of YM-1 
for 6 hours. Cells lysates were analyzed by Western blot (A). Densitometry analysis 
of Akt-1, Akt2, and pAkt S473 levels shown as % of vehicle treatment ± SD (B). 
Comparison of densitometry analysis between MB and YM-1 treatment-dependent 
Akt reductions shown as % of vehicle treatment ± SD (C) 
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Figure 3.4. Oncogenic factors less affected than Akt by YM-1 treatment. 
MCF7 cells were treated with noted concentrations of YM-1 for 6 hours. Cells lysates 
were analyzed by Western blot (A). Densitometry analysis of (total) Akt, ERα, p53, 
and RAS levels shown as % of vehicle treatment ± SD (B). 
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Chapter 43: 
 
Overcoming Akt-dependent Tamoxifen Resistance by Inhibiting 
Hsp70 
 
Abstract 
 The major survival kinase Akt can regulate numerous 
tumorigenic and pro-survival pathways. These regulated pathways can 
include mechanisms that can induce resistance to chemotherapeutics. 
Thus, reducing Akt activity or levels is considered a promising anti-
cancer and therapy sensitization strategy. We have previously 
demonstrated that inhibitors of the 70-kDa heat shock protein (Hsp70) 
family can clear Akt. However, the potential impact of this activity on 
regulating resistance was not clear. Here, we demonstrate that 
treatment of tamoxifen resistant cells with an Hsp70 inhibitor, YM-1, 
for only 4 hours restored tamoxifen sensitivity; likely through Akt 
dependent mechanisms. The ability to restore tamoxifen sensitivity 
                                                             
3 Portions of these results were previously published (John Koren III, Yoshinari Miyata, Janine Kiray, John 
C. O’Leary III, Lana Nguyen, Jianping Guo, Laura J. Blair, Xioakai Li, Umesh K. Jinwal, Jin Q. Cheng, Jason 
E. Gestwicki, Chad A. Dickey. PLoS One. 2012;7(4):e35566. Epub 2012) and are used with permission of 
the publisher. 
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was due to a mechanism involving phosphorylation of estrogen 
receptor. Conversely, an Hsp70 activator facilitated the emergence of 
tamoxifen resistance in naïve cells. Together, these findings provide a 
potential strategy for the treatment of standard and refractory cancer 
types, which would be expected to have multiple clinical applications 
for breast cancer. 
 
Introduction 
 Breast cancers also have a high prevalence of mutations; 
mutations which can promote tumorigenesis and survival (Hudis and 
Gianni, 2011). While these mutations produce targets for treatments, 
other mutations can overcome signaling cascade network circuitry to 
eliminate upstream targets (Oliveira et al., 2005; Uray and Brown, 
2011). This reduces the number of potential targets, reducing the 
cadre of treatment options, and increasing the potential for resistance 
genesis. In addition, resistance can emerge when regulatory proteins 
are altered to allow pro-survival proteins to act unabated. Several 
kinases related to cell survival have been implicated in facilitating 
chemotherapy resistance (Brognard et al., 2001; Campbell et al., 
2001; Clark et al., 2002; Guo et al., 2010; Sun et al., 2001). Thus, 
strategies to re-sensitize refractory cancer cells to existing therapies 
are sorely needed. 
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 A majority of breast cancer patients have estrogen receptor 
alpha (ERα)-positive tumorw which respond to anti-estrogen therapy 
(Lin et al., 2010; McDonnell and Wardell, 2010; Rivera-Guevara and 
Camacho, 2011; Shanle and Xu, 2011). The binding of estradiol, a 
predominant estrogen, to ERα ultimately leads to the transcription of 
pro-proliferation genes such as c-myc, cathepsin D, and transforming 
growth factor-α (Nicholson et al., 1999). The compound 4-
hydroxytamoxifen (4-OHT) or its pro-drug Tamoxifen is an ERα 
antagonist that has been used to prevent the transcription of pro-
survival genes (Rivera-Guevara and Camacho, 2011). However, the 
emergence of resistance to 4-OHT in tumor cells diminishes the long-
term efficacy of this approach (Katzenellenbogen et al., 1997). A 
common cause for the emergence of 4-OHT refractory breast cancer is 
post-translational modifications of ERα, particularly phosphorylation. 
Specifically, a major regulator of cancer pathogenesis, Akt, often 
facilitates 4-OHT-insensitivity in breast cancer cells by phosphorylating 
ERα (Campbell et al., 2001; Lannigan, 2003; Park et al., 2008; Sun et 
al., 2001; van Agthoven et al., 2009a; van Agthoven et al., 2009b). 
 Akt (protein kinase B, PKB/AKT) is a major regulator of the PI3K 
signal transduction pathway, as well as a key pro-survival/anti-
apoptosis kinase (Cardone et al., 1998; Castaneda et al., 2010; Chen 
et al., 2001; Kennedy et al., 1999; Kops et al., 1999; Romashkova 
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and Makarov, 1999). Akt is often chronically activated in a variety of 
cancers (Brognard et al., 2001; Campbell et al., 2001; Clark et al., 
2002; She et al., 2008; Sun et al., 2001), and it is associated with the 
development of resistance to chemotherapeutics including TAM/4-OHT 
and others (Brognard et al., 2001; Campbell et al., 2001; Clark et al., 
2002; Sun et al., 2001). Akt1 and Akt2 (PKBα and PKBβ) can each 
phosphorylate ERα at Ser-167. This enhances ERα transcriptional 
activity independent of estrogen binding, allowing tumor cells to grow 
in the presence of this common therapeutic (Campbell et al., 2001; 
Lannigan, 2003; Meijer et al., 2006; Park et al., 2008; Sun et al., 
2001; van Agthoven et al., 2009a; van Agthoven et al., 2009b) We 
propose that reducing levels of total Akt, rather than selectively 
targeting a single member, might not only be therapeutically beneficial 
for certain types of cancers, but it may also be a plausible strategy for 
restoring sensitivity to tumors that have developed resistance to 
standard therapies. 
 One potential way to reduce the levels of Akt is to manipulate 
the molecular chaperone system to promote Akt clearance. The family 
of 70kDa heat shock proteins (Hsp70) represents a major portion of 
the chaperone repertoire and it stabilizes a number of oncogenic client 
proteins, including Akt (Gao and Newton, 2002; Koren et al., 2010; 
Shiota et al., 2010). Phenothiazine compounds, such as methylene 
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blue and azure C, are low potency Hsp70 inhibitors that generate 
cytotoxicity in a number of breast cancer cell lines by depleting Akt 
levels (Koren et al., 2010). As described in the previous chapter, the 
rhodacyanine YM-1 is capable of total Akt reduction and at 
concentrations lower than MB. These data provided a proof-of-concept 
study: depletion of Akt levels based on Hsp70 modulation could be a 
novel strategy for treating refractory breast cancers when aberrant Akt 
activity is driving the resistance.  
 Here, we use YM-1; a compound previously shown to potently 
and selectively reduce the protein levels of both Akt1 and Akt2. The 
loss of Akt activity restored tamoxifen sensitivity in a previously 
resistant cell model. These studies suggest possible therapeutic 
approaches for successful implementation of this strategy in a clinical 
setting. 
 
Methods 
Cell Lines 
 Tamoxifen resistant (TR-MCF7) and parental MCF7 cells were 
generously provided by Dr. Jin Q. Cheng of Moffitt Cancer Center 
(Tampa, FL). 
 
Antibodies, siRNAs, and Chemicals 
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 Anti-ERα, and pERα S167 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Anti-Actin was purchased from Sigma 
Aldrich (St. Louis, MO). Anti-Hsp90ß (H90-10) was generously 
provided by Marc B. Cox (University of Texas, El Paso). All siRNAs 
were purchased from Qiagen and used as previously described (Koren 
et al., 2010). SW02 was synthesized as previously described (Wisen et 
al., 2008). YM-1 was synthesized as described (Kawakami et al., 
1998).  
 
Cell Culture and Transfections 
 MCF7 cells were grown as previously described (Koren et al., 
2010).  TR-MCF7 cells were grown in DMEM (described with MCF7 
cells) supplemented with 10µM 4-OHT. siRNA transfections were 
performed using SilentFect (Bio-Rad) and incubated as directed for 48 
h before harvest or treatment. 
 
Protein Collection, Quantitation, and Western Blotting 
 Cells were harvested by application of mammalian protein 
extraction reagent (Thermo) as previously described (Koren et al., 
2010). Protein level measurement, equilibration, western blotting, and 
detection were performed as previously described (Koren et al., 2010). 
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Lactate Dehydrogenase (LDH) Assay 
 Indicated cell lines were plated in designated medium. Once cells 
reached ~95% confluency, YM-1 or vehicle was applied in fresh DMEM 
without phenol red. At described times following application of 
treatment condition, medium was collected from each treatment and 
centrifuged to pellet dead cells and debris. Protocol was followed as 
supplied from Cytotox-96 kit (Promega). 
 
MTT Cell Viability Assay 
 TR-MCF7 cells were plated in a 96well plate in medium 
containing 10µM 4-OHT. When cells reached ~90% confluency cells 
were treated in OPTI-MEM in one of four conditions 1: DMSO (vehicle) 
or varied concentrations of YM-1 for 48 h. 2: Vehicle or varied 
concentrations of YM-1 for 4 h followed with exchange of YM-1 
medium with 4-OHT medium. 3: Vehicle or varied concentrations of 
YM-1 for 4 h followed with exchange of YM medium with medium 
containing a vehicle treatment for 4-OHT (volume matched 95% 
EtOH). Or, 4: 10µM 4-OHT in OPTI-MEM for the full 48 h of 
experiment. MTT assay kit was purchased from ATCC and assay was 
run as per supplied protocol. 
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Cell Proliferation Assays 
 MCF7 cells were plated at 10,000cells/mL. 24 h after plating, 
chemical compounds (vehicle or 50µM SW02) were applied to the cells 
in OPTI-MEM. After 24 h incubation in SW02 or vehicle medium was 
exchanged with medium containing 10µM 4-OHT. 48 h post 4-OHT 
addition, medium was removed and cells were simultaneously fixed 
and stained with a 0.1% crystal violet in 30% MeOH for 20 minutes. 
Excess dye was washed off with water. 10% Acetic acid solution was 
used to free the bound crystal violet. Absorbance of released crystal 
violet was read at 570nm on NanoDrop spectrophotometer (Thermo). 
 
Isolation of Nuclear Proteins 
 TR-MCF7 cells were grown in designated medium in 10cm 
dishes. Cells were treated for 4 h with 10µM 4-OHT, 10µM YM-1, both 
or vehicle(s) for both compounds. Following incubation, cells were 
harvested and nuclear proteins isolated using reagents and supplied 
protocol from the Qproteome Nuclear Protein Kit (Qiagen). 
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Results 
Limited Toxicity from Brief YM-1 Treatments 
 YM-1 efficacy was tested in a cell model of tamoxifen-resistance. 
The toxicity of YM-1 in a refractory tamoxifen (4-OHT) resistant MCF7 
(TR-MCF7) cell line was compared to that of the parental MCF7 (non-
resistant) cell line. Indeed, YM-1 effectively killed both standard and 
resistant (TR-MCF7) cells after 48-hour incubation (Figure 4.1A). 
Given the previous concerns with chronic MKT-077 (the parent 
compound of YM-1) treatment (Britten et al., 2000; Propper et al., 
1999), we speculated that a shorter treatment with YM-1 might be 
equally toxic. To test this, MCF7 cells and TR-MCF7 cells were treated 
with 10µM YM-1 for 4 hours. This was removed and replaced with 
vehicle for 44 hours. In addition, TR-MCF7 cells were treated with 
either 4-OHT or the vehicle for 4-OHT (95% EtOH) (Figure 4.1B). In 
each case, minimal toxicity was observed. 
 
Overcoming 4-OHT Resistance with YM-1 
 Cell viability (MTT) assays were then used to test whether this 
shorter treatment strategy was affecting cell proliferation. The TR-
MCF7 cells were grown in media containing 10µM 4-OHT. Our designed 
treatment strategy contained four conditions all terminating at 48 
hours: 1. 10µM 4-OHT alone for 48 hours, 2. YM-1 (or vehicle) 
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treatment for 4 hours followed by re-addition of 10µM 4-OHT for 44 
hours, 3. YM-1 (or vehicle) treatment for 4 hours followed by 95% 
EtOH (vehicle for 4-OHT), and 4. YM-1 (or vehicle) treatment for the 
full 48-hours. MTT assays revealed that the 4-hour 10µM YM-1 
followed by 10µM 4-OHT treatment reduced viability by 60% relative 
to the 4-OHT treatment alone. The 10µM YM-1 followed by 95% EtOH 
treatment did not alter viability (Figure 4.2A). The 48-hour 10µM YM-
1 treatment reduced viability by 40% compared to 48-hour 4-OHT 
treatment, similar to Figure 4.1A.  
 All treatment strategies containing YM-1 were analyzed by two-
way ANOVA (Figure 4.2B). This analysis revealed a significant effect 
by treatment strategy and concentration of YM1 (F(4, 30)=41.04, 
p<0.0001), (F(2,30)=54.22, p<0.0001). The interaction between 
treatment strategy and concentration was not significant 
(F(8,30)=1.83, p=0.1107). Bonferroni post-hoc analysis of this 2-way 
ANOVA showed no significant differences between any of the 
concentrations used for the 48-hour YM-1 treatment and the 4-hour 
YM-1 followed by 95% EtOH treatment (all p>0.05); whereas, all the 
concentrations used for the 4-hour YM-1 followed by 4-OHT treatment 
were significantly different from the 4-hour YM-1 followed by 95% 
EtOH treatment (all p<0.05). All the concentrations of the 4-hour YM-1 
followed by 4-OHT and the 48-hour YM-1 were significantly different 
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(all p<0.05) with the exception of the 10µM YM-1 concentration 
(p>0.05). We attributed the lack of significance to the general toxicity 
caused by the 48-hour 10µM concentration of YM-1 (see Figure 4.1A 
& B). A one-way ANOVA of the YM-1 concentration curve for the 4 
hour YM-1 treatment followed by 44 hours of 4-OHT treatment 
revealed that the 10µM concentration was significantly different from 
all other concentrations (F(4,10)=16.49, p=0.0002)(Figure 4.2C). 
The concentration curve for the 4 hour YM-1 treatment followed by 
95% EtOH treatment displayed that no concentration was significant 
from any other concentration by one-way ANOVA (F(4,10)=3.435, 
p=0.0516)(Figure 4.2D). Comparison of all of the 48 hour YM-1 
concentrations, by one-way ANOVA, displayed that, again, the 10µM 
concentration was significantly different from all other concentrations 
in this treatment (F(4,10)=12.32, p=0.0007)(Figure 4.2E). We 
continued our analysis by comparing the 10µM YM-1 concentration, 
from all treatment groups, with the null treatment. Viability values of 
all aforementioned treatment conditions, with the inclusion of the 4-
OHT 48 hour treatment and vehicle treatments as separate groups, 
were analyzed by one-way ANOVA (F,(5,12)=24.33, p<0.0001). 
Tukey’s post-hoc test revealed that 4 hour YM-1 followed by 4-OHT 
was significantly different from the 4-OHT 48 hours treatment 
(p<0.05), whereas both the 48 hour 10µM YM-1 and the 4 hour 10µM 
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YM-1 followed by 95% EtOH treatments were not significantly different 
from the 4-OHT 48 hour treatment (Figure 4.2F). This analysis also 
displayed that 10µM YM1 followed by 4-OHT is significantly different 
from 10µM YM1 followed by 95% EtOH (p<0.05). 
 
ERα Phosphorylated at Akt Consensus Site Reduced by Brief YM-1 
Treatment 
 These findings suggested that just a 4 hour treatment of 10µM 
YM-1 could re-sensitize TR-MCF7 cells to tamoxifen/4-OHT, stopping 
cell growth without causing overt toxicity. The potential mechanisms 
for this phenomenon were then explored.  One plausible mechanism 
was aberrant kinase activity, which is known to promote tamoxifen 
resistance by phosphorylating ERα at a site known to promote 
estrogen independent activity (Brognard et al., 2001; Campbell et al., 
2001; Clark et al., 2002; Guo et al., 2010; Sun et al., 2001). We 
treated TR-MCF7 cells as described for the experiments in Figure 4A & 
B. Nuclear proteins were isolated and probed for levels of ERα pS167, 
a site that when phosphorylated conveys tamoxifen independence. 
Indeed, phosphorylation of ERα pS167 was elevated in the presence of 
4-OHT; however, the addition of 10µM YM-1 abrogated this event 
(Figure 4.3A & B). YM-1 did not alter the localization of ERα (Figure 
4.3C & D).  
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Hsp70 Silencing Different from Inhibition 
 Following observation of the Akt effects, we wished to determine 
if Hsp70 siRNA, silencing expression of Hsp72, would act in a similar 
manner to Hsp70 inhibition. This experiment could also demonstrate if 
Hsp70 is not involved directly in the resistance machinery. Hsp70 
siRNA increases Akt levels. Thus, if Hsp70 is not involved then the 
increased Akt should enhance the resistance mechanisms compared 
with the cells treated with a control non-silencing siRNA. To test this 
hypothesis, TR-MCF7 cells were transfected with Hsp70 or control 
siRNA.  Surprisingly, the data supported neither hypothesized 
outcome. Silencing of Hsp70 in the presence of 4-OHT had no impact 
versus control siRNA. The cells were equally resistant (Figure 4.4A). 
This data suggests that the observed mechanism is due in combination 
to Akt reductions as well as loss of Hsp70 activity. Thus, increasing Akt 
levels and increasing Hsp70 activity should promote a resistance 
phenotype. 
 
Generation of 4-OHT Resistance by Hsp70-activator 
 Previous work from our lab demonstrated that compounds which 
enhance Hsp70 activity can preserve Akt levels (Koren et al., 2010). 
This compound, SW02, increases Hsp70 ATP-hydrolysis rates as well 
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as stabilizes Akt. SW02 was also shown to rescue the toxicity in cancer 
cells observed following treatment with an Hsp70 inhibitor (see 
Chapter 2).  We pre-treated naïve MCF7 cells with 50µM SW02 prior to 
application of 4-OHT to test if it could induce a resistance to 4-OHT. 
Indeed, SW02 enhanced proliferation in the presence of 4-OHT 
(Figure 4.4B). This finding, coupled with the Hsp70 silencing not 
behaving like an Hsp70 inhibitor, suggests that, though necessary, Akt 
is not alone in the generation of this particular resistance mechanism. 
Hsp70 clearly plays a crucial role in the induction and maintenance of 
resistance mechanisms.  
 
Discussion 
 Here we define a strategy supporting the use of Hsp70 inhibiting 
compounds for breast cancers refractory from aberrant Akt activity. 
This outcome seems dependent on chaperone-mediated regulation of 
Akt stability (Figure 4.5). While the effects on Akt cannot be solely 
ascribed to the restoration of sensitivity to tamoxifen, the work 
presented here strongly supports further investigation into depleting 
total levels of all Akt members as a therapeutic strategy for breast 
cancer and possibly other cancers driven by alterations in the 
PI3K/PTEN/Akt pathway. 
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 While other kinases have been identified to phosphorylated ERα 
(Guo et al., 2010), Akt is a major survival kinase, regardless of 
resistance phenotype, and its clearance could enhance the efficacy of 
chemotherapeutics. If our hypothesis that YM-1 is an Hsp70 inhibitor is 
accurate, this clearance could be due to enhanced ubiquitination of 
Akt, as the ubiquitin ligase for Akt, CHIP (carboxy terminus of Hsc70 
interacting protein)(Dickey et al., 2008), is known to interact with 
Hsp70 (Qian et al., 2006). 
 There are comparisons to be made to the use of Hsp90 inhibitors 
as a cancer therapy (Beliakoff and Whitesell, 2004). Hsp90 inhibitors 
have also been used in clinical trials, but these have met with greater 
success largely due to the discovery of geldanamycin, a natural 
inhibitor of Hsp90, which guided many of the medicinal chemistry 
approaches that have led to those now being tested in humans. 
However, there is one feature of Hsp90 inhibitors that may ultimately 
lead the downfall of this approach for cancer; the secondary induction 
a heat shock response. Induction of heat shock proteins are pro-
survival and can prevent apoptosis in some cancers (Afanasyeva et al., 
2007; Dudeja et al., 2009; Jiang et al., 2009; Kong et al., 2011). This 
does not occur when Hsp70 is inhibited. In fact, the levels of inducible 
Hsp70 are often slightly reduced compared to vehicle treatment 
(Jinwal et al., 2009; Koren et al., 2010). Thus, while depletion of 
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constitutive Hsp90 members may be less toxic than depletion of 
constitutive Hsp70 members in general, inhibition of Hsp70 may 
ultimately be more effective due to this non-specific consequence of 
Hsp90 inhibition. 
 Despite these data supporting Hsp70 inhibition as a treatment 
strategy for Akt-driven cancers, it is possible that Hsp70 inhibition will 
cause toxicity in normal tissues when administered systemically. With 
this in mind, we sought to determine whether a separate 
therapeutically-relevant application of Hsp70 inhibitors could be 
identified that would reduce the potential for toxic side-effects. We 
speculated that Hsp70 inhibitors could open the door for longer 
intervals between treatments and reducing the likelihood for off-target 
toxicities. In further support of this idea, Akt members, which are 
primary targets of Hsp70 inhibition, are major players in the 
generation of resistance to a number of therapeutics (Brognard et al., 
2001; Campbell et al., 2001; Clark et al., 2002; Sun et al., 2001). 
Akt2 in particular is a primary kinase of ERα phosphorylation, a 
modification that facilitates resistance to tamoxifen in MCF7 cells (Sun 
et al., 2001). Interestingly, Akt2 was the most sensitive of the Akt 
members to Hsp70 inhibition in these studies (see Ch.2: Figure 3A & 
B). 
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 Here, we demonstrated that by incorporating our knowledge of 
chaperone- and Akt-mediated resistance mechanisms, we were able to 
determine the specific mechanism of action for the effects of YM1 in 
MCF7 cells. Not only does this study show that brief treatments with 
an Hsp70 inhibitor could be an effective strategy for restoring 
sensitivity to compounds with known toxicity profiles, but also shows 
that mechanisms can be used to define the efficacy of drugs. 
 Tamoxifen therapies typically fail due to the development of 
resistance. Acquired resistances take time to develop. Our studies 
have demonstrated that brief treatments with YM1 can re-sensitize 
refractory cancers to tamoxifen. The benefit of such a short treatment 
is the lack of opportunity for a resistance to YM1 itself as well as 
reduced likelihood for off-target toxicities. Moreover, the ability to 
negate existing resistances allows for the reintroduction of putative 
chemotherapies; preventing the need for more costly and potentially 
dangerous secondary and tertiary therapeutic strategies. These patient 
benefits coupled with the high number of cancer varieties linked to Akt 
dysfunction provides a platform for the continued study and 
development of new compounds to deplete Akt through manipulation 
of this Hsp70 inhibitor scaffold. 
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Figure 4.1. TR-MCF7 cells and MCF7 cells susceptible to YM-1 toxicity at 48 
hours but not at 4 hours; tamoxifen does not alter cytotoxicity. TR-MCF7 and 
parental MCF7 cells were treated for 48 hours in with 10µM YM-1. After 48 hours, 
media were collected and analyzed by LDH assay. Values shown are a % of vehicle 
treatment ± SD (A). MCF7 cells were treated for 4 hours with 10µM YM-1. At 4 
hours, medium was replaced with standard growth media for 44 hours. TR-MCF7 
cells were treated with 10µM YM-1 for 4 hours. At 4 hours, the media was removed 
and replaced with standard TR-MCF7 media containing 10µM 4-OHT or 95% EtOH, 
the vehicle for 4-OHT, for 44 hours. After 48 hours from initial treatment, media 
were collected and analyzed by LDH assay. Values shown are a % of vehicle 
treatment ± SD (B). 
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Figure 4.2. Brief exposure to YM-1 restores tamoxifen effect in resistant cell 
model. TR-MCF7 cells were treated with 4-OHT for 48 hours, YM-1 (or vehicle) for 4 
hours followed by 44 hours of either 4-OHT or 95% EtOH, or YM-1 (or vehicle) for 48 
hours. At 48 hours from initial treatment, MTT viability assays were performed. 
Viability values of each treatment as a % of 48 hours of 4-OHT treatment ± SD (A). 
2-Way ANOVA analysis comparing all YM-1 treatment groups ( - 4-hour YM-1then 
4-OHT, - 48 hour YM-1, - 4-hour YM-1 then 95% EtOH),  revealed significance 
across concentrations (F(2,30)=54.22, p<0.0001), and treatment strategy (F(4, 
30)=41.04, p<0.0001), but no significant interaction (F(8,30)=1.83, p=0.1107). * - 
indicates significant difference (p<0.05) of 4-hour YM-1 then 4-OHT from other two 
groups with exception of 10µM treatments, significance as indicated (ns = 
p>0.05)(B). 1-way ANOVA of YM-1 + 4-OHT strategy revealing significance of 10µM 
concentration (F(4,10)=16.49, p=0.0002)(C). Analysis of YM-1 + 95% EtOH, by 1-
way ANOVA, revealed no significance across tested concentrations (F(4,10)=3.435, 
p=0.0516)(D). 48-hour YM-1 treatment showed significance differences between all 
concentrations and the 10µM concentration, by 1-way ANOVA (F(4,10)=12.32, 
p=0.0007)(E). 1-way ANOVA analysis (F,(5,12)=24.33, p<0.0001) comparing all 
10µM YM-1 treatments, 48-hour 4-OHT, and vehicle treatments revealed no 
significant difference between 48-hour 4-OHT and both 4-hour 10µM YM-1 + 95% 
EtOH and 48-hour 10µM YM-1 treatments; whereas the 48-hour 4-OHT and the 4-
hour 10µM YM-1 + 95% EtOH were significantly different from the 4-hour YM-1 + 4-
OHT treatment (p<0.05)(F). 
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Figure 4.3. Phosphorylation but not localization of Estrogen Receptor α 
altered by YM-1. TR-MCF7 cells were treated with indicated conditions for 4 hours. 
Nuclear isolates and cytosolic fractions were compared by Western blot, 
representative blots shown (A & C). Densitometry analysis of pERα and ERα levels 
displayed as % of vehicle treatment ± SD (B & D). 
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Figure 4.4. Hsp70 siRNA does not alter resistance; tamoxifen resistance 
induced by Hsp70 ATPase activator. TR-MCF7 cells were transfected with non-
silencing control or Hsp72 siRNA. 48 hours after transfection, cells were grown in 
medium containing vehicle (95% EtOH), 5µM, or 10µM 4-OHT. 48 hours after 4-OHT 
addition cells were simultaneously fixed and stained with 0.1% Crystal violet solution 
in 30% methanol. Crystal violet was released from cells by addition of 10% acetic 
acid. Acetic acid solution was collected and analyzed on spectrophotometer as 
measure of relative percent growth (A). MCF7 cells were treated with 50µM of an 
Hsp70 activator, SW02, or vehicle (DMSO) for 24hrs. Medium was then changed to 
new medium supplemented with 10µM 4-OHT for 48 hours. 48 hours after 4-OHT 
addition, cells were fixed, stained and analyzed as above. Relative percent growth as 
measured by spectrophotometer ± S.D. (white bar, DMSO; gray bars, SW02)(B). 
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Figure 4.5. Model for predicted re-sensitization pathway following Hsp70 
inhibition. Depicted are two accepted pathways for ERα transcriptional regulation, 
either in the presence of estradiol or via an alternative, Akt dependent, mechanism 
in the presence of the anti-estrogen, 4-OHT. The addition of an Hsp70 inhibitor – 
compounds having now been demonstrated to reduce Akt – prevents the 
phosphorylation of ERα by Akt. Thus, Hsp70 inhibition leads to a reacquisition of 
sensitivity to 4-OHT. 
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Chapter 5: Conclusions 
 
 In this study, we have illustrated the regulation of the 
chaperone/client relationship and how this relationship can be 
manipulated to produce a variety of outcomes. Here, we have shown 
that Hsp70 ATPase inhibitors can produce cytotoxicity in breast cancer 
cell models. These compounds not only inhibit Hsp70 but also clear 
Akt. This Akt clearance is dependent on Hsp70 levels and can be 
rescued with Hsp70 activating compounds. We also demonstrated that 
brief treatment with an Hsp70 ATPase inhibitor can facilitate the 
overcoming of resistance to tamoxifen in a tamoxifen resistant breast 
cancer cell line and that this resistance can be generated using an 
Hsp70 activator. 
 The molecular chaperone Hsp70 has long been implicated as a 
prosurvival factor in human cancers. Recently, work has focused on 
the anti-cancer potentials of Hsp70 inhibitors (Evans et al., 2010; Leu 
et al., 2009; Leu et al., 2011; Powers et al., 2010) and genetic 
silencing of the cytosolic Hsp70 family members (Guo et al., 2005; 
Havik and Bramham, 2007; Powers et al., 2008). Beyond the direct 
prosurvival abilities of Hsp70, it has been demonstrated that Hsp70 
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regulates the function and stability of other prosurvival proteins. The 
use of these crude Hsp70 ATPase inhibitors demonstrates the high 
potential these compounds and backbones possess. In cells facing high 
metabolic and proteostatic demands, Hsp70 and its family members 
are crucial elements that, once inhibited, can be targeted readily with 
seemingly little insult to other “normal” cell types. Here, we 
demonstrated that multiple classes of Hsp70 inhibitors all produce 
reductions in Akt as well as cancer cell exclusive cytotoxicity. 
 These studies remain inconclusive due to mechanistic difficulties 
brought about by the nature of the Hsp70/Hsc70/Akt relationship. We 
demonstrate that the action of these compounds is reduced in the 
absence of Hsp70. However, we recognize that Hsc70 is also a likely 
target; especially since the interactions of MB and rhodacyanines have 
been shown with Hsc70 but not Hsp70 (Jinwal et al., 2009; Rousaki et 
al., 2011). The unfortunate limitation with examining this further is the 
induction of Hsp70 observed following Hsc70 silencing. In order to 
effectively show that the toxicity and Akt effects are dependent on the 
cytosolic Hsp70 chaperones we would have to silence both Hsp70 and 
Hsc70. This strategy carries a large pitfall in that dual silencing of both 
cytosolic Hsp70 members results in cell death (Powers et al., 2008). 
Thus, we could not properly demonstrate in a cell model the exact 
mechanism of these compounds; though we do acknowledge the 
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likelihood of pluripotent mechanisms playing a role in the observed 
data. 
 We were also unable to elucidate the exact mechanisms behind 
the overcoming of resistance phenomena. The literature suggests 
some evidence that supports how, beyond the Akt aspects explored by 
our group, inhibition of Hsp70 can lead to changes in ERα activity. It 
has been shown that Hsc70 can bind to an unliganded ERα and 
abrogating activity (Ogawa et al., 2005). Low levels of Hsp70 were 
found to improve the effectiveness of aromatase inhibitors in patients, 
a therapy to block estrogen production (Yiu et al., 2010). However, 
silencing of Hsp70 did not alter the behavior of 4-OHT-resistant MCF7 
cells to 4-OHT. This was interesting since silencing of Hsp70 increases 
Akt levels. Our hypothesis was that the absence of Hsp70 could 
perhaps alter the resistance phenotype similar to the use of the Hsp70 
inhibitors; or would increase in Akt levels and thus drive the resistance 
mechanisms producing, again, an altered phenotype. Neither of these 
outcomes was validated by the data. This suggested to us that it was 
not only the absence of Hsp70 activity but also the reduction in Akt 
levels that produced the overcoming of resistance.  
 While more work needs to be done to validate the mechanisms 
and specific targets of these compounds, there is much that can be 
taken away from these studies. The ability of two highly homologous 
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compounds, Hsp70 and Hsc70, to regulate a single client in such 
dramatically opposite ways deserves further study. The area most 
distinct between Hsp70 and Hsc70 are in the substrate binding domain 
with a 31% difference (Callahan et al., 2002). If we were to 
understand the relationship between which clients preferred which 
chaperone in relation to the cellular environment it would then be 
possible to selectively target just one of the Hsp70 family members to 
clear an aberrant client. 
 This option of selective targeting of a chaperone would be a step 
forward from the current work being conducted on Hsp90 inhibitors. 
Though Hsp90 inhibitors have demonstrated success in the lab and 
clinical trials (Beliakoff and Whitesell, 2004; Hostein et al., 2001; Modi 
et al., 2007; Pacey et al., 2010; Pacey et al., 2011; Rajan et al., 2011) 
they could be improved upon. Hsp90 inhibitors have the unfortunate 
effect of causing an induction of the other stress-inducible heat shock 
genes. As mentioned throughout this manuscript, many of the 
inducible heat shock genes are anti-apoptotic and are often linked to a 
negative prognosis in cancer (Dudeja et al., 2009; Garrido et al., 
2003; Jiang et al., 2009; Rashmi et al., 2004; Sliutz et al., 1996; 
Vargas-Roig et al., 1997; Vargas-Roig et al., 1998; Yano et al., 1996). 
While Hsp90 regulates numerous oncogenic and prosurvival clients, 
the act of induction, increasing Hsp72 levels, following Hsp90 inhibition 
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abrogates the ability of Hsp90 inhibitors in cancer cells. In fact, this 
issue has been addressed in the literature demonstrating increased 
Hsp90 inhibitor efficacy under conditions depleting Hsp72 (Bagatell et 
al., 2000; Davenport et al., 2010; Guo et al., 2005). Another related 
strategy could be to inhibit the heat shock response via heat shock 
factor (HSF) regulation (Whitesell and Lindquist, 2009). This would 
lead to no induction of stress response proteins following Hsp90 
inhibition; a result similar to Hsp72 depletion. 
 There is another class of heat shock protein which could provide 
new targets for cancer therapy; the 40-kDa heat shock proteins, or 
Hsp40. Hsp40s, or J proteins, have a highly conserved ≈70 amino acid 
region, the J domain (Kampinga and Craig, 2010). These J proteins are 
thought to present Hsp70 with client proteins as well as stimulate ATP 
hydrolysis (Johnson and Craig, 2001). If true, and there is a J protein 
that has specificity for Akt, or any oncogenic client protein, it could be 
possible to determine what governs the J protein/Akt relationship and 
perhaps then promote that interaction to clear specifically Akt. 
 Hsp70 is a vital target in the treatment of cancer. Understanding 
client processing under distinct environmental conditions could lead to 
advanced therapeutics channeling specific client proteins to specified 
fates. The use of Hsp70 inhibitors could also be used in combination 
with Hsp90 inhibitors and with other chemotherapies known to induce 
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Hsp72. All of these strategies, along with the search for more potent 
inhibitors, increase our knowledge of how the molecular chaperone 
pathways affect disease, not only cancer, but any disease involving 
aggregation, preserved mutation, or aberrant function. Eventually, we 
may be able to manipulate the chaperone network in a manner to 
target a distinct client protein. This makes the future of Hsp70, and 
the rest of the molecular chaperones, very exciting; especially 
considering the dependence of cancer cells on the Hsp70 family. 
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Appendix A (continued) 
 
 
 
Figure A1.  In-Cell-Western Standard Curve. HeLa cells were plated at 40% 
confluency in 96-well plates and transfected with Akt or control siRNA for 72 hours. 
Akt antibody was applied at indicated dilutions. Akt knockdown was detectable down 
to a 1:800 dilution. GAPDH (green) was used to estimate toxicity and cell adhesion. 
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Appendix A (continued) 
 
 
 
Figure A2.  Overexpression of Hsp70 enhances MB and AC clearance of Akt. 
HeLa cells were transfected with Myc-Hsp70 or empty vector, cells were then treated 
in increasing doses with Hsp70 ATPase inhibitors methylene blue (MB) and Azure C 
(AC); experiments were analyzed by Western Blot (A). 
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